AstraZeneca (AZN) Suspends Buybacks; Aims to Maintain Financial Flexibility

AstraZeneca (NYSE: AZN) announced that it is suspending share repurchases with
immediate effect. During 2012 the company has completed net share repurchases
of $2.3 billion in respect of its initial target of $4.5 billion.

AstraZeneca confirms its Core EPS target range for the Full Year 2012 is
maintained at $6.00 to $6.30.

Pascal Soriot, Chief Executive Officer, AstraZeneca said: "As I assume my new
responsibilities at AstraZeneca, I believe this is a prudent step that
maintains flexibility while the Board and I complete the company's ongoing
annual strategy update."

In line with usual practice, AstraZeneca will update the market on the outlook
for 2013 in conjunction with the Full Year 2012 Financial Results announcement
in January.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BofA maintains underperform ratings on six BDC stocks
• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce